These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Odom GL; Gregorevic P; Allen JM; Finn E; Chamberlain JS Mol Ther; 2008 Sep; 16(9):1539-45. PubMed ID: 18665159 [TBL] [Abstract][Full Text] [Related]
29. Use of imaging biomarkers to assess perfusion and glucose metabolism in the skeletal muscle of dystrophic mice. Ahmad N; Welch I; Grange R; Hadway J; Dhanvantari S; Hill D; Lee TY; Hoffman LM BMC Musculoskelet Disord; 2011 Jun; 12():127. PubMed ID: 21639930 [TBL] [Abstract][Full Text] [Related]
30. Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy. Wasala NB; Bostick B; Yue Y; Duan D Hum Mol Genet; 2013 Jul; 22(13):2634-41. PubMed ID: 23459935 [TBL] [Abstract][Full Text] [Related]
32. Photobiomodulation therapy protects skeletal muscle and improves muscular function of mdx mice in a dose-dependent manner through modulation of dystrophin. Albuquerque-Pontes GM; Casalechi HL; Tomazoni SS; Serra AJ; Ferreira CSB; Brito RBO; de Melo BL; Vanin AA; Monteiro KKDS; Dellê H; Frigo L; Marcos RL; de Carvalho PTC; Leal-Junior ECP Lasers Med Sci; 2018 May; 33(4):755-764. PubMed ID: 29209866 [TBL] [Abstract][Full Text] [Related]
33. Ghrelin improves muscle function in dystrophin-deficient mdx mice by inhibiting NLRP3 inflammasome activation. Chang L; Niu F; Chen J; Cao X; Liu Z; Bao X; Xu Y Life Sci; 2019 Sep; 232():116654. PubMed ID: 31306657 [TBL] [Abstract][Full Text] [Related]
34. Intermittent PTH treatment improves bone and muscle in glucocorticoid treated Mdx mice: A model of Duchenne Muscular Dystrophy. Yoon SH; Grynpas M; Mitchell J Bone; 2019 Apr; 121():232-242. PubMed ID: 30716510 [TBL] [Abstract][Full Text] [Related]